Diagnosis and treatment of rituximab-induced acute tumor lysis syndrome in patients with diffuse large B-cell lymphoma

American Journal of the Medical Sciences

Volumn 343, Issue 4, 2012, Pages 337-341

  Yang, Bo ^a   Lu, Xue Chun ^a   Yu, Rui Li ^a   Chi, Xiao Hua ^b   Zhang, Wen Ying ^a   Zhu, Hong Li ^a   Yuan, Jing ^a   Zhao, Po ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b The Second Artillery General Hospital   (China)

Author keywords

Acute tumor lysis symptom; Diagnosis; Diffuse large B cell lymphoma; Non Hodgkin's lymphoma; Treatment

Indexed keywords

ALLOPURINOL; BICARBONATE; CALCIUM; CD20 ANTIGEN; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; PHOSPHORUS; PIRARUBICIN; POTASSIUM; PREDNISONE; RITUXIMAB; URIC ACID; VINDESINE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACIDOSIS; AGED; ARTICLE; ARTIFICIAL VENTILATION; BONE MARROW BIOPSY; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CASE REPORT; COLOSTOMY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG DOSE INCREASE; DYSPNEA; ECHOGRAPHY; GASTROINTESTINAL BIOPSY; HEART PALPITATION; HEMICOLECTOMY; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; JAUNDICE; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LIVER FAILURE; MALAISE; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; NAUSEA; NAUSEA AND VOMITING; OXYGEN SATURATION; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; RESPIRATORY FAILURE; TACHYPNEA; TUMOR LYSIS SYNDROME; TUMOR VOLUME; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; VOMITING; WEIGHT REDUCTION;

EID: 84859031232     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318244db6f     Document Type: Article

References (23)

1. Abu-Alfa AK, Younes A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am J Kidney Dis 2010;55:S1-3; quiz S14-9.
2. Mughal TI, Ejaz AA, Foringer JR, et al. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev 2010;36:164-76.
3. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993;94:133-9. (Pubitemid 23046437)
4. Tosi P, Barosi G, Lazzaro C, et al. Consensus conference on the management of tumor lysis syndrome. Haematologica 2008;93: 1877-85.
5. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29:2-9. (Pubitemid 34171789)
6. Bienvenu J, Chvetzoff R, Salles G, et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2001;2:378-84. (Pubitemid 34048661)
7. Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 1999;18:465-71. (Pubitemid 30365324)
8. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127:3-11. (Pubitemid 39331101)
9. Jensen M, Winkler U, Manzke O, et al. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 1998;77:89-91. (Pubitemid 28425183)
10. Francescone SA, Murphy B, Fallon JT, et al. Tumor lysis syndrome occurring after the administration of rituximab for posttransplant lymphoproliferative disorder. Transplant Proc 2009;41:1946-8.
11. Jabr FI. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma. Int J Hematol 2005;82:312-4. (Pubitemid 43329742)
12. Otrock ZK, Hatoum HA, Salem ZM. Acute tumor lysis syndrome after rituximab administration in Burkitt's lymphoma. Intern Emerg Med 2008;3:161-3.
13. Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999;62:247-50.
14. Abou Mourad Y, Taher A, Shamseddine A. Acute tumor lysis syndrome in large B-cell non-Hodgkin lymphoma induced by steroids and anti-CD 20. Hematol J 2003;4:222-4. (Pubitemid 36789978)
15. Cohen LF, Balow JE, Magrath IT, et al. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med 1980;68: 486-91. (Pubitemid 10141811)
16. Kunkel L, Wong A, Maneatis T, et al. Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefitrisk update. Semin Oncol 2000;27:53-61. (Pubitemid 32166264)
17. Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone - results of a multicenter phase III study. J Clin Oncol 2010;28:4207-13.
18. Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001;19:697-704. (Pubitemid 32119083)
19. Senbanjo IO. Tumor lysis and acute renal failure in Burkitt's lymphoma: a review on pathophysiology and management. Indian J Nephrol 2009;19:83-6.
20. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001;97:2998-3003.
21. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 2011;364:1844-54.
22. van den Berg H, Reintsema AM. Renal tubular damage in rasburicase: risks of alkalinisation. Ann Oncol 2004;15:175-6. (Pubitemid 38139621)
23. Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010;149:578-86.